RNTX — Rein Therapeutics Share News
0.000.00%
Last trade - 00:00US FDA puts on hold Rein Therapeutics' lung disease drug trial (updated)
Brief: Rein Therapeutics Paused Its Phase 2 Renew Trial Of Lti-03 In The U.S.
Rein Therapeutics pauses dosing in lung disease trial after US FDA places hold
Brief: Rein Therapeutics Announces First Patient Dosed In Renew Phase 2 Trial Of Lti-03 In Patients With Ipf
Rein Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Rein Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Update
Brief: Rein Therapeutics Announces Initiation Of Renew Phase 2 Trial Of Lti-03 In Patients With Ipf
Rein Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview
Brief: Rein Therapeutics Granted Two Patents Covering The Novel Formulation And Administration Methods Of Dry Powder LTI-03 For Treatment Of Respiratory Diseases
Brief: Aileron Therapeutics Announces Rebranding To Rein Therapeutics
Aileron Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Aileron Therapeutics Announces Positive Topline Data From Cohort 2 Of The Phase 1B Clinical Trial Of LTI-03 In Idiopathic Pulmonary Fibrosis
Aileron Therapeutics Inc expected to post a loss of 41 cents a share - Earnings Preview
Aileron Therapeutics Inc expected to post a loss of 41 cents a share - Earnings Preview
Brief: Aileron Therapeutics And Advancium Health Network Announce An Exclusive Option Agreement For The Acquisition Of ALRN-6924 For Retinoblastoma
Aileron Therapeutics Inc expected to post a loss of 41 cents a share - Earnings Preview
Brief: Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis
Aileron Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Aileron Therapeutics Inc expected to post a loss of 42 cents a share - Earnings Preview